Conavi Research Underscores Hybrid IVUS-OCT Edge as Next-Gen System Awaits FDA Review

An update from Conavi Medical ( (TSE:CNVI) ) is now available.

Conavi Medical highlighted new peer-reviewed research in Cardiovascular Research showing that deep learning-based plaque characterization using hybrid IVUS-OCT imaging outperforms single-modality approaches and human experts in cadaveric heart studies. The findings, supported by international imaging and AI experts, bolster the clinical and commercial rationale for hybrid intravascular imaging in more precise, image-guided coronary interventions.

The company is advancing its next-generation Novasight hybrid IVUS-OCT platform, which has been submitted to the U.S. Food and Drug Administration for regulatory clearance as it readies for broader commercialization and clinical adoption. Conavi also granted long-term incentive stock options to its chief financial officer, Mark Quick, covering 1,000,000 common shares at an exercise price of $0.41, subject to regulatory approvals, signaling continued investment in its leadership team during this expansion phase.

The most recent analyst rating on (TSE:CNVI) stock is a Buy with a C$1.00 price target. To see the full list of analyst forecasts on Conavi Medical stock, see the TSE:CNVI Stock Forecast page.

More about Conavi Medical

Conavi Medical is a Toronto-based medical technology company focused on designing, manufacturing, and marketing imaging systems that guide minimally invasive cardiovascular procedures. Its flagship Novasight Hybrid System combines intravascular ultrasound and optical coherence tomography in a single device, offering simultaneous, co-registered imaging of coronary arteries with regulatory clearance in the U.S., Canada, China, and Japan.

Average Trading Volume: 42,876

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$22.97M

For an in-depth examination of CNVI stock, go to TipRanks’ Overview page.